SCHEMBL3014581

SCHEMBL3014581

COc1ccc(-c2csc(N3CCC(S(=O)(=O)c4c(C(C)C)cc(C(C)C)cc4C(C)C)CC3)n2)c(OC)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.46
CYP1A1 P04798 2/20 0.43
CYP1B1 Q16678 2/20 0.43
RAB9A P51151 6/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
REV1 Q9UBZ9 1/20 0.41
MAPT P10636 8/20 0.40
NPC1 O15118 4/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
NFKB1 P19838 2/20 0.39
NFKB2 Q00653 2/20 0.39
RELA Q04206 2/20 0.39
ATM Q13315 1/20 0.39
LMNA P02545 3/20 0.39
TDP1 Q9NUW8 1/20 0.39
KDM4E B2RXH2 1/20 0.38
GAA P10253 1/20 0.38
HSD17B10 Q99714 2/20 0.37
ALDH1A1 P00352 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3007130 0.93 REV1 (0.48) ARRAB9ASMN1; SMN2REV1MAPT
SCHEMBL3004587 0.90 AR (0.45) ARRAB9ASMN1; SMN2REV1MAPT
SCHEMBL3008234 0.88 SMN1; SMN2 (0.55) ARRAB9ASMN1; SMN2MAPTNPC1
SCHEMBL3011788 0.86 MAPT (0.47) ARCYP1A1CYP1B1RAB9ASMN1; SMN2
SCHEMBL3014196 0.85 MAPT (0.53) SMN1; SMN2MAPTMEN1KMT2ALMNA
SCHEMBL3010531 0.85 SMN1; SMN2 (0.44) CYP1A1CYP1B1RAB9ASMN1; SMN2MAPT
SCHEMBL3017832 0.85 AR (0.54) ARCYP1A1CYP1B1RAB9ASMN1; SMN2
SCHEMBL3018661 0.84 SMN1; SMN2 (0.54) RAB9ASMN1; SMN2MAPTNPC1MEN1
SCHEMBL3007049 0.84 F2RL3 (0.36) RAB9ASMN1; SMN2MAPTMEN1KMT2A
SCHEMBL3015692 0.84 AR (0.48) ARCYP1A1CYP1B1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885CYP1A1 4605/4885CYP1B1 4305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.